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Abstract
The aim of this study was to study the serotypes and clonal diversity of pneumococci caus-
ing invasive pneumococcal disease in Catalonia, Spain, in the era of 13-valent pneumococ-
cal conjugate vaccine (PCV13). In our region, this vaccine is only available in the private
market and it is estimated a PCV13 vaccine coverage around 55% in children. A total of
1551 pneumococcal invasive isolates received between 2010 and 2013 in the Molecular
Microbiology Department at Hospital Sant Joan de Déu, Barcelona, were included. Fifty-
two serotypes and 249 clonal types—defined by MLST—were identified. The most common
serotypes were serotype 1 (n = 182; 11.7%), 3 (n = 145; 9.3%), 19A (n = 137; 8.8%) and 7F
(n = 122; 7.9%). Serotype 14 was the third most frequent serotype in children < 2 years (15
of 159 isolates). PCV7 serotypes maintained their proportion along the period of study,
16.6% in 2010 to 13.4% in 2013, whereas there was a significant proportional decrease in
PCV13 serotypes, 65.3% in 2010 to 48.9% in 2013 (p<0.01). This decrease was mainly
attributable to serotypes 19A and 7F. Serotype 12F achieved the third position in 2013 (n =
22, 6.4%). The most frequent clonal types found were ST306 (n = 154, 9.9%), ST191 (n =
111, 7.2%), ST989 (n = 85, 5.5%) and ST180 (n = 80, 5.2%). Despite their decrease,
PCV13 serotypes continue to be a major cause of disease in Spain. These results empha-
size the need for complete PCV13 vaccination.
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Introduction
Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, especially
among young children and the elderly. This pathogen colonizes the nasopharynx as part of the
normal flora in children [1] and is the leading bacterial cause of pneumonia, sepsis and menin-
gitis [2]. During asymptomatic nasopharyngeal colonization stages, S. pneumoniae interplays
with the host immune system through multiple and complex interactions. Imbalance due to
host factors and microbiological factors are related with the propensity to cause serious inva-
sive disease [3]. The capsule of pneumococcus is its main virulence factor. There are over 97
known serotypes but not all of them have the same capacity to cause invasive pneumococcal
disease (IPD) [4].
Despite the high effectiveness reported for PCV7 worldwide [5–8], the lower vaccine sero-
type coverage found in some countries compared to the USA [9] made necessary the develop-
ment of two new conjugate vaccines, PCV10 and PCV13, which included a larger number of
serotypes. PCV13 vaccine includes serotypes 1, 3, and 5 that were common in Europe, Asia,
and Africa, and also serotype 6A, 7F and 19A. The majority of these serotypes had emerged
after the implementation of PCV7 in our region [10].
Of note, although the Vaccination Advisory Committee of the Spanish Association of Pedi-
atrics has recommended the routine administration of conjugate pneumocccal vaccines (PCV7
since 2001–2010 and currently PCV13) these vaccines have not been financed by the Catalan
Public Health System and they have been only available in the private market. In our reference
area, we estimated a PCV7 vaccination coverage of 47% in 2007 [10] and a PCV13 vaccine cov-
erage of 55% in 2013 [11].
Although differences in the capsular type are the major determinant of the invasive disease
potential of a strain, several studies have suggested that differences in both the invasive disease
potential and the ability to cause disease are also influenced by the genetic background [12–
14].
The aim of this study was to determine the pneumococcal serotypes and clonal types caus-
ing IPD in Catalonia, Spain, in the era of PCV13.
Materials and Methods
This research was approved by the Ethics and Clinical Research Committee from Hospital Sant
Joan de Déu. No consent was asked to participants because the data were analyzed
anonymously.
This was a prospective study which included all pneumococcal invasive isolates, adults and
children, received between 2010 and 2013 from 26 health centers in Catalonia that were char-
acterized by the Molecular Microbiology Department at University Hospital Sant Joan de Déu
in Barcelona, Spain. In 2009, this laboratory was designated by the government of Catalonia,
Spain, for molecular surveillance of invasive pneumococcal disease. In Catalonia, with a popu-
lation of around 7 million and 1.4 million persons aged 18 years or younger, these 26 health
centres captured 40.1% of all hospital admissions during 2012 [15].
On December 9, 2009, the European Medicine Agency (EMA) authorized the commerciali-
zation of Pneumococcal Conjugate Vaccine 13 (PCV13) in Europe [16]. Although in Catalonia
the pneumococcal conjugate vaccine has not yet been incorporated into the official vaccination
calendar, PCV13 was included in the schedule recommended by the Spanish Association of
Paediatrics in 2010 [17]. In fact, many paediatricians recommend this vaccine in their private
practices, and vaccination coverage was estimated at 55.1% for PCV13, 12.5% for PCV7 and
1.4% for PCV10 vaccine in 2013 [11].
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IPD was defined as the presence of clinical findings of infection together with isolation by
culture of S. pneumoniae in sterile fluid samples (blood, cerebrospinal fluid or any other sterile
fluid).
Microbiological identification and antimicrobial susceptibility
All pneumococcal invasive isolates were cultured on blood agar plates (Columbia agar supple-
mented with 5% sheep blood; bioMérieux) and were identified in the different health centers
by standard microbiological methods including optochin sensitivity test and an antigenic test.
The minimum inhibitory concentrations (MIC) to antibiotics were determined with the agar
dilution technique. Antibiotic susceptibilities were defined according to the breakpoints of the
European Committee on Antimicrobial Susceptibility Testing (EUCAST) [18]. Multidrug
resistance was defined as non-susceptibility to three or more antimicrobial agents [19].
Serotype analysis. The identification of capsular pneumococcal serotypes was performed
at our laboratory using multiplex PCR combined with fragment analysis and automated fluo-
rescent capillary electrophoresis. This technique implemented in our Molecular Microbiology
Department in 2010 and allows the detection of 40 serotypes/serogroups: (1, 2, 3, 4, 5, 6A/6B,
6C, 7F/7A, 7C/(7B/40), 8, 9V/9A, 9N/9L, 10A, 10F/(10C/33C), 11A/11D/11F, 12F/(12A/44/
46), 13, 14, 15A/15F, 15B/15C, 16F, 17F, 18/(18A/18B/18C/18F), 19A, 19F, 20, 21, 22F/22A,
23A, 23B, 23F, 24/(24A/24B/24F), 31, 33F/(33A/37), 34, 35A/(35C/42), 35B, 35F/47F, 38/25F,
and 39) [20]. Pneumococcal strains were also sent to the National Center for Microbiology of
Majadahonda (Madrid, Spain) to complete the serotype detection with Quellung reaction [21]
and the antimicrobial susceptibility study.
Clonal analysis. Clonal analysis was performed with multilocus sequence typing (MSLT).
MLST was performed as reported elsewhere [22]. The assignment of alleles and sequence types
(ST) was carried out using the software at the pneumococcal web page http://pubmlst.org/
spneumoniae/. Analysis of ST and assignment to clonal complex were performed with the
eBURST program [23]. STs that shared six of seven allelic (single locus [SLV]) variants were
considered a clonal complex.
Statistical analysis
We used the X2 test or Fisher’s exact test to compare proportions. Statistical analyses were per-
formed using SPSS for Windows, version 17.0 (SPSS). We calculated 95% CIs, and 2-sided P
values< .05 were considered to be statistically significant.
Genetic diversity of isolate populations was estimated using Simpson’s numerical index of
discrimination (SID), using the website: www.comparingpartitions.info. To compare the SID
values from the different groups of data the p value was calculated using the online tool avail-
able in the same web page.
Results
During the study period a total of 1576 pneumococcal invasive isolates were received, of which
25 were not viable for clonal analysis and serotyping. A total of 1551 strains (98.4%) were
included in the study; serotype identification was performed in all of them. Among the 1551
isolates, 910 (58.7%) were from males and 641 (41.3%) from females, with a mean age of 50.7
years. 159 (10.2%) isolates were from children less than 2 years old, 143 (9.2%) from the age
group between 2 to less than 5 years, 76 (4.9%) from the age 5 to less than 18 years, 561
(36.1%) from the age 18–65 and 612 (39.4%) in patients older than 65 years old.
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All 1551 isolates of IPD had positive cultures: blood (1400), pleural fluid (78), cerebral spi-
nal fluid (58), peritoneal fluid (2), joint fluid (5), ascites liquid (5) and pericardial fluid (1). In
two of the positive cultures the sample type was not reported.
The most important clinical manifestation in the study period was pneumonia (n = 1078,
69.5%), including the diagnostics of non-complicated pneumonia (n = 980, 63.2%) and compli-
cated pneumonia (n = 98, 6.3%), followed by bacteremia/sepsis (n = 315, 20.3%) and meningi-
tis (n = 127, 8.2%). During the study period, although pneumonia stayed as the main clinical
manifestation, a change in the proportion of the other diagnoses was observed. The proportion
of meningitis and complicated pneumonia decreased from 44 cases (10.3%) and 29 cases
(6.8%) in 2010 to 21 cases (6.1%) and 14 cases (4.1%) in 2013, with p = 0.116 and p = 0.110,
respectively. On the other hand, there was a significant increase in the proportion of cases with
bacteremia/sepsis from 68 cases (15.9%) in 2010 to 86 cases (25.1%) in 2013, p = 0.010. Accord-
ing to age group, pneumonia was the main clinical manifestation diagnosed in all ages except
in the group of children less than 2 years old where it was overcome by bacteremia/sepsis.
During the study period most of the S. pneumoniae invasive isolates were susceptible to the
majority of the antibiotics analyzed. Penicillin (meningeal breakpoints), erythromycin and tet-
racycline presented a similar proportion of resistant isolates during the study period: 23.6%,
19.2% and 22.2%, respectively. Chloramphenicol, cefotaxime and levofloxacin showed lower
proportions of resistance: 7%, 3% and 1%, respectively. However, three serotype 19A isolates
(clonal type ST320) showed a MIC to cefotaxime4 μg/ml. These strains were isolated in one
child and two adults with pneumonia. No isolates were resistant to vancomycin. Overall, the
proportion of multiresistance presented in the study was 13.2%. No significant differences in
the rate of MDR were observed when comparing PCV13 serotypes vs non-PCV13 serotypes.
Children less than 2 years old showed significantly higher proportion of MDR compared to
older patients: 49 of 159 (30.8%) vs 156 of 1392 (11.2%) (p<0.01).
Serotype distribution of invasive isolates
Overall, 52 different serotypes were found. The most common serotypes found were serotype 1
(n = 182, 11.7%), serotype 3 (n = 145, 9.3%), serotype 19A (n = 137, 8.8%) and serotype 7F
(n = 122, 7.9%) (Fig 1). In total, 14.9% were serotypes included in PCV7, 55.6% were serotypes
included in PCV13 and 44.4% were non-vaccine serotypes.
According to age group, in children less than 2 years old the main serotypes were serotype
19A (n = 32, 20.1%), serotype 24F (n = 17, 10.7%) and serotype 14 (n = 15, 9.4%). In the age
group between 2 and 5 years old, the most common serotype was serotype 1 (n = 48, 33.6%), as
well as in the age group between 5 years old and 18 (n = 45, 59.2%). In the group between 18
years old and 65, the main serotypes were 7F (n = 62, 11.05%), 1 (n = 61, 10.9%) and 12F
(n = 52, 9.3%). And in the age group older than 65 the main serotypes were serotypes 3 (n = 77,
12.6%), 19A (n = 60, 9.8%) and 14 (n = 45, 7.3%).
According to year, in 2010 the most common serotypes were serotype 19A (n = 52, 12.2%),
serotype 7F (n = 46, 10.8%) and serotype 1 (n = 45, 10.5%). In 2011, the main serotypes found
were serotypes 1 (n = 42, 10.2%), 3 (n = 41, 10%) and 19A (n = 39, 9.5%). In 2012, the most
common serotypes were serotype 1 (n = 53, 14.3%), 12F (n = 34, 9.2%) and 3 (n = 29, 7.8%).
And in 2013, they were serotypes 1 (n = 42, 12.2%), 3 (n = 34, 9.9%), 12F (n = 22, 6.4%) and 14
(n = 22, 6.4%).
During the study period there was an evolution in the serotypes included in the different
conjugate vaccines. The serotypes included in the PCV7 maintained their proportion along the
period of study, 16.6% in 2010 to 13.4% in 2013, whereas there was a significant proportional
decrease in PCV13 serotypes from 65.3% in 2010 to 48.9% in 2013 (p<0.01). Consequently,
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non-PCV13 serotypes showed a proportional significant increase, from 34.7% in 2010 to 51%
in 2013 (p<0.01) (Table 1).
Clonal diversity of serotypes
Overall, we identified 249 ST in the study, 45 of which were new (ST5223, ST5224, ST5686,
ST5687, ST5688, ST5823, ST5824, ST5825, ST5826, ST5829, ST6004, ST6005, ST6006,
ST6166, ST6394, ST6395, ST6518, ST6519, ST6520, ST6521, ST6999, ST7000, ST7001,
ST7002, ST7314, ST7855, ST8077, ST8492, ST9038, ST9039, ST9040, ST9041, ST9419,
ST9420, ST9421, ST9439, ST9440, ST9441, ST9737, ST9738, ST9742, ST9755, ST9756,
ST9758, ST9942). Eight of these new STs also presented one new allele (ST8492, ST9439,
ST9440, ST9441, ST9755, ST9756, ST9758 and ST9942). The most frequent clonal types found
in the study were ST306 (n = 154, 9.9%), ST191 (n = 111, 7.2%), ST989 (n = 85, 5.5%) and
Fig 1. Frequency of serotypes causing invasive pneumococcal disease during the years 2010, 2011, 2012 and 2013.
doi:10.1371/journal.pone.0151125.g001
Table 1. Serotype distribution according to age group and year.
PCV7(%) PCV10(%) PCV13(%) Non PCV13(%)
Age group
<2 years old 34 (21.4) 50 (31.4) 94 (59.1) 65 (40.9)
2 to <5 years old 20 (14.0) 82 (57.3) 102 (71.3) 41 (28.7)
5 to <18 years old 4 (5.3) 56 (73.7) 61 (80.3) 15 (19.7)
18 to 65 years old 81 (14.4) 210 (37.4) 297 (52.9) 264 (47.1)
>65 years old 92 (15.0) 163 (26.6) 309 (50.5) 303 (49.5)
Year
2010 71 (16.6) 182 (42.6) 279 (65.3) 148 (34.7)
2011 60 (14.6) 144 (35.1) 231 (56.3) 179 (43.7)
2012 54 (14.6) 128 (34.5) 185 (49.9) 186 (50.1)
2013 46 (13.4) 107 (31.2) 168 (48.9) 175 (51.0)
doi:10.1371/journal.pone.0151125.t001
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ST180 (n = 80, 5.2%). A population snapshot of the 1551 isolates based on an eBURST analysis
was represented in Fig 2. The major clonal complexes found were CC306, CC191, CC156,
CC180, CC230, CC433, CC53 and CC320. Thirty-three STs expressed serotypes that were not
present in the MLST database showing potential capsular switching (ST53, ST63, ST109,
ST193, ST205, ST280, ST306, ST310, ST338, ST405, ST605, ST646, ST871, ST989, ST1046,
ST1143, ST1167, ST1201, ST1816, ST2013, ST2217, ST2372, ST2557, ST2670, ST3133,
ST4310, ST4475, ST4828, ST5033, ST5224, ST5688, ST6532 and ST8300).
Table 2 shows the different ST expressed by the different serotypes found in our collection,
and the clonal diversity of each serotype was determined using the Simpson’s Index of Diver-
sity (SID).
Discussion
The results obtained in this study allowed us to observe the evolution experienced by serotypes
after the introduction of PCV13 in our geographical area. After the introduction of the vaccine
and, similarly to other countries with higher vaccine coverage, there has been a significant pro-
portional decrease in the PCV13 serotypes and, as a consequence, a proportional increase of
non-PCV13 serotypes [24–28]. However, PCV13 serotypes continue to be responsible for a
high burden of the disease, probably due to the low vaccine coverage which is estimated in only
40% of target population in our geographical area [13]. Despite this limited coverage, serotypes
19A and 7F experienced an important decrease during the study period; a similar decrease was
not observed for serotypes 1, 3 and 14. In the non-vaccine serotypes group, it is worth mention-
ing the increase observed for serotype 12F along the study period, and compared with previous
data obtained before the introduction of PCV13 in our region [29]. This increase was also
Fig 2. Clonal population of pneumococcal isolates obtained from 2010 to 2013 based on an eBURST analysis.
doi:10.1371/journal.pone.0151125.g002
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Table 2. Clonal diversity of serotypes causing IPD.
Serotype SIDa CI (95%) n° CLONAL TYPES
1 0.283 0.200–0.367 182 217(1)/228(3)/303(1)/304(19)/306(153)/1310(1)/1311(2)/3081(1)/9942(1)
3 0.635 0.569–0.701 145 53(1)/180(79)/260(31)/458(1)/505(5)/1220(23)/1377(2)/1380(1)/3794(1)/9420(1)
19A 0.830 0.788–0.872 137 63(1)/162(1)/199(7)/202(1)/230(1)/276(19)/320(46)/416(1)/871(1)/994(4)/1167(6)/1201(15)/1611(2)/2013(22)/
2102(1)/3259(2)/4475(1)/4831(1)/6005(1)/6166(2)/8077(1)/9742(1)
7F 0.201 0.104–0.298 122 191(109)/393(1)/1589(2)/2372(1)/3133(1)/3490(1)/3544(5)/3609(1)/4771(1)
14 0.586 0.472–0.700 102 9(4)/13(1)/15(1)/63(1)/124(1)/143(9)/156(65)/162(1)/409(1)/433(1)/557(5)/782(1)/790(1)/1556(1)/2128(1)/
2944(1)/4573(1)/5193(2)/6519(1)/6520(1)/7002(1)/9038(1)
12F 0.272 0.160–0.384 99 218(2)/989(84)/2013(1)/4833(10)/8060(2)
8 0.631 0.525–0.736 77 53(44)/404(16)/989(1)/1110(4)/1480(1)/1629(4)/3225(3)/3406(1)/4960(1)/5205(1)/9039(1)
22F 0.251 0.111–0.391 67 433(58)/698(2)/819(1)/1372(2)/2557(1)/5826(1)/7314(2)
24F 0.690 0.612–0.769 65 72(2)/162(1)/177(3)/230(22)/646(1)/3980(2)/4253(2)/4677(29)/5033(1)/6532(2)
6C 0.779 0.667–0.892 41 224(6)/386(2)/1143(1)/1150(1)/1692(5)/1714(2)/2670(2)/3261(1)/4310(18)/5688(1)/9418(1)/9441(1)
9N 0.772 0.662–0.881 37 66(16)/67(6)/280(1)/405(1)/517(6)/3982(2)/5140(2)/5824(1)/6004(1)/6037(1)
10A 0.123 1.000–0.278 32 97(30)/1208(1)/5686(1)
4 0.825 0.693–0.957 29 205(12)/244(1)/246(1)/247(2)/1729(2)/1866(2)/2333(2)/2358(1)/4795(2)/6006(1)/6999(1)/9419(1)/9756(1)
11A 0.571 0.401–0.741 29 62(18)/408(1)/1010(1)/5298(1)/6521(7)/9440(1)
16F 0.817 0.729–0.906 28 30(8)/383(2)/570(9)/1840(1)/5829(1)/6395(2)/7006(3)/8492(1)/9758(1)
5 0.510 0.382–0.638 27 289(9)/1223(17)/3339(1)
23A 0.587 0.369–0.804 25 42(16)/438(1)/2319(1)/2670(2)/2829(3)/5825(1)/9439(1)
23B 0.157 1.000–0.348 25 1373(1)/2372(23)/7001(1)
9V 0.740 0.649–0.831 25 156(1)/162(3)/280(9)/838(9)/4306(3)
6B 0.793 0.629–0.958 24 90(1)/138(1)/176(2)/315(1)/386(11)/1624(1)/1668(1)/2467(1)/3614(1)/5687(2)/6394(1)/7000(1)
15A 0.640 0.410–0.870 23 63(14)/193(1)/605(1)/861(1)/1262(1)/1577(1)/5139(1)/5224(1)/7856(1)/9041(1)
19F 0.943 0.896–0.990 21 51(3)/87(2)/89(1)/177(2)/179(2)/180(1)/425(1)/1167(4)/2100(1)/2307(1)/5194(1)/5827(1)/9421(1)
15B 0.912 0.851–0.974 19 193(2)/474(1)/1262(4)/1577(1)/3669(1)/4828(4)/5223(2)/5224(2)/8300(1)/9040(1)
6A 0.901 0.794–1.000 19 224(1)/327(1)/338(1)/473(1)/490(2)/919(1)/1143(6)/1150(1)/1692(1)/2611(2)/3981(1)/3986(1)
31 0.419 0.140–0.698 17 1684(2)/1766(13)/3360(1)/7855(1)
23F 0.765 0.631–0.898 17 81(5)/109(7)/277(1)/311(1)/338(2)/439(1)
33F 0.758 0.617–0.900 16 673(2)/717(4)/1012(7)/2223(1)/4668(2)
38 0.385 0.092–0.678 14 310(2)/393(11)/1201(1)
18C 0.718 0.570–0.866 13 110(4)/113(6)/205(1)/1233(2)
15C 0.844 0.743–0.946 10 63(1)/193(3)/1262(3)/4828(1)/5224(2)
17F 0.417 0.047–0.786 9 310(1)/392(7)/9738(1)
35B 0.750 0.579–0.921 9 198(3)/558(4)/2690(1)/4346(1)
35F 0.933 0.805–1.000 6 676(1)/2217(2)/6518(1)/9737(1)/9755(1)
34 0.000 0.000–0.000 5 1046
20 0.700 0.349–1.000 5 235(3)/1794(1)/2369(1)
29 0.833 0.583–1.000 4 1816(1)/558(2)/2217(1)
11F 0.000 0.000–0.000 4 62
21 0.667 0.667–0.667 4 193(2)/432(2)
13 0.000 0.000–0.000 2 923
7A 0.000 0.000–0.000 2 191
9L 1.000 1.000–1.000 2 66(1)/405(1)
25 1.000 1.000–1.000 1 393
27 1.000 1.000–1.000 1 1475
28 1.000 1.000–1.000 1 5823
24B 1.000 1.000–1.000 1 230
(Continued)
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noticed in the post PCV13 studies of Israel, Germany and Uruguay previously cited [24,26,28].
In our study, a low index of diversity of serotype 12F was observed, with high proportion of
ST989, a clonal type previously detected in children with meningitis in Gambia [30]. Also
interesting, serotype 24F was the second most common serotype in children less than 2 years
old during the study period when analyzing the results by age groups. The major clone detected
in serotype 24F was ST230, a multidrug resistant clone related with the increase of serotype
19A in Bulgaria, Portugal and in our geographical area [29,31,32]. A previous study conducted
in our area also observed an increase in the rate of serotype 24 several years after PCV7 intro-
duction associated with the clonal expansion of this genotype [33].
The clonal analysis of serotype 19A revealed the important presence of the multiresistant
clone ST320 in 46 of 137 (33.5%) serotype 19A isolates, but a high index of clonal diversity was
found which reflects the high adaptation of this serotype. The association of serotype 19A with
ST320 was previously described in our area as a contributor to the emergence of this serotype
after the introduction of PCV7 [34]. The high proportion of ST320 among our isolates (three
of them showing high resistance to cefotaxime) is worrisome as well as the still high presence
of this serotype despite being included in PCV13, which highlights the need for complete vacci-
nation to prevent disease caused by this serotype.
A worrying result is the proportionally high prevalence of serotype 14 found in our results.
This serotype was included in PCV7, the first generation of conjugate vaccines available in
Spain since 2001. While other PCV7 serotypes were almost non-existent in our study, serotype
14 continues to be one of the most prevalent in younger children and older people. Its clonal
composition revealed that ST156 was detected in more than 65 of 102 (63%) serotype 14 iso-
lates. A previous study performed by our group found that the pilus was present in all ST156
strains analyzed, while its general presence in the other clonal types was not frequent [35]. A
study performed by Barocchi et al. showed in a murine model that a strain with pilus was more
virulent than its non-piliated mutant [36]. Moreover, a study by Sjöström et al. suggested that
the expression of pili in ST156 isolates contributed to the successful spread of this clone world-
wide [37]. Although undoubtedly the low coverage of conjugate vaccines in our population
could be facilitating its spread, we hypothesize that the high presence of this virulence factor in
the serotype 14 isolates of our geographical area could be also related to the persistence of its
circulation and their high invasiveness. Further studies are needed to know why serotype 14
continues to be so prevalent in our population.
Also noteworthy were the results about serotype 3. The present study confirms the results
obtained for this serotype in previous publications of our group ranking as the second serotype
Table 2. (Continued)
Serotype SIDa CI (95%) n° CLONAL TYPES
11C 1.000 1.000–1.000 1 53
39 1.000 1.000–1.000 1 6040
18A 1.000 1.000–1.000 1 241
18B 1.000 1.000–1.000 1 113
18F 1.000 1.000–1.000 1 4863
22A 1.000 1.000–1.000 1 2557
NT 2
Total 1551
a SID, Simpson’s Index of Diversity. Years 2010, 2011, 2012 and 2013.
doi:10.1371/journal.pone.0151125.t002
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more frequently found causing IPD. In our previous studies serotype 3 was also found respon-
sible of a high burden of disease in our area when detection and capsular typing was performed
in direct sample by molecular techniques [38–40]. These results differ from the ones previously
obtained from Brueggemann et al. in England where serotype 3 was only found in carriage
[41]. Contradictory results have also been found with respect the clonal diversity of this sero-
type. Studies from Scotland and Singapore described a high clonal diversity for this serotype,
while studies from Canada and The Netherlands found strong clonal homogeneity of serotype
3 in their countries [42–45]. In our study a low index of diversity was found with CC180,
which comprises ST180 and three SLV (ST3794, ST1380 and ST9420), being the major clonal
type detected among serotype 3 isolates in our geographical area (82 of 145 isolates, 56.5%). In
contrast, ST180 was associated with a small number of IPD cases in a pediatric study per-
formed in the US during the 2008–2013 period [46].
Conclusion
In conclusion, despite the observed decrease of PCV13 serotypes, these serotypes continue to
be the major serotypes causing invasive disease in our geographical area. These results empha-
size the need for complete PCV13 vaccination in children to cover the main affected popula-
tion and also to ensure the protection obtained by herd immunity. The study of the genetic
population of the serotypes circulating in a geographical area might help to obtain useful infor-
mation about temporal trends, geographical differences and changes in invasiveness.
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